Equipment purchase and leasehold improvements for a 30,210 square food facility for the pharmaceutical manufacturer, allowing Biosimilar Solutions to manufacture affordable medicine more efficiently and operate at full capacity.The facility will be retrofit for biosimilar production, which involves creating biological products highly similar to the U.S.FDA-approved reference products.Biosimilar Solutions will undertake a blend of gene therapy, virus, biological drug substance, and drug product manufacturing.

This investment will finance equipment purchases, tenant improvements, and working capital associated with research and development expenses for the development of a 35,000 sq. ft. pharmaceutical manufacturing facility in Aguadilla, Puerto Rico.The new manufacturing facility will allow the company to focus on research and development associated with the manufacturing of late-stage clinical biologics and gene therapy via biosimilar production.The new facility will create new accessible jobs for low-income people within the local community.